홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Droxidopa

HCID 92974
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
23651-95-8
표준 SMILES
N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1
InChIKey
QXWYKJLNLSIPIN-JGVFFNPUSA-N
분자식
C9H11NO5
평균 분자량
213.19 g/mol
단동위원소 질량
213.06372245

개요

Droxidopa is a serine derivative that is L-serine substituted at the beta-position by a 3,4-dihydroxyphenyl group. A prodrug for noradrenalone, it is used for treatment of neurogenic orthostatic hypotension. It has a role as an antihypertensive agent, a prodrug and a vasoconstrictor agent. It is a L-tyrosine derivative and a member of catechols.

이름 및 식별자

우선 이름
Droxidopa
IUPAC
(2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid
영어명
DROXIDOPA
분자식
C9H11NO5
분자량
213.19

이름 및 동의어

droxidopa23651-95-8L-DOPSDOPS(2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acidNortherathreo-DopaserineL-threo-DOPSL-ThreodopsL-dihydroxyphenylserinedroxidopumSM 5688
이름 더 보기
L-threo-3,4-DihydroxyphenylserineDroxidopa (JAN)roxidopaDroxydopaDroxidopa>Droxidopa-13C6
L-threo-dihydroxyphenylserineL-Tyrosine, beta,3-dihydroxy-, threo-CHEBI:31524J7A92W69L7DTXSID6046422threo DOPSthreo-DOPS(-)-(2S,3R)-2-AMINO-3-(3,4-DIHYDROXYPHENYL)-3-HYDROXYPROPANOIC ACID

데이터베이스 식별자

CAS
23651-95-8、3916-18-5
PubChem CID
92974
DTXSID
DTXSID201017236
ChEMBL
CHEMBL2103827
ChEBI
CHEBI:31524
UNII
24A0V01WKS、J7A92W69L7
EC Number
223-480-5、688-528-3
Nikkaji
J22.085J

물성

구조 계산 물성

XLogP
-3.2
극성 표면적
124 Ų
수소 결합 공여자 수
5
수소 결합 수용자 수
6
회전 가능 결합 수
3
무거운 원자 수
15
형식 전하
0
복잡도
235

실험 및 물리화학적 성질

DrugsPharmaceuticals -> Listed in ZINC15
Human Drugs · 2건

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

물리화학적 성질

녹는점
232 · 232-235° (dec); mp 229-232° (dec) (Ohashi)
끓는 점
549.8 · 549.8±50.0 °C(Predicted)
밀도
1.608 · 1.608±0.06 g/cm3(Predicted)
저장 조건
-20 °C · -20°C
용해도
3 mg/mL · DMSO: ≥3mg/mL
물리적 상태
가루
산도 계수 (pKa)
2.09 · 2.09±0.24(Predicted)
색상
흰색에서 황갈색까지
Merck
14 · 14,3457
안정성
흡습성
InChI
InChI=1/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/s3
InChIKey
QXWYKJLNLSIPIN-WWXSATIUNA-N
SMILES
[C@H](C1C=CC(O)=C(O)C=1)(O)[C@H](N)C(=O)O |&1:0,10,r|

화학적 성질

Off-White Solid

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 6건

Warning

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 42 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Warning

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]

유해성 정보

Hazard Classes and Categories · 2건

Skin Irrit. 2 (100%)

Skin Irrit. 2 (100%)

독성 정보

Hepatotoxicity · 1건

Liver test abnormalities have not been reported in patients taking droxidopa, but the agent has had limited clinical use. There were no episodes of clinically apparent liver injury reported in the preregistration trials of droxidopa, and since its approval there have been no published reports of droxidopa hepatotoxicity. Thus, liver injury from droxidopa is likely to be rare, if it occurs at all.

Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Droxidopa

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

안전 데이터

wgk
3
rtecs
VT9626010
HS 번호
29225090
risk_code
36/37/38
hazard_code
Xi
safety_code
26
Hazard Classifications
Eye Irrit. 2Skin Irrit. 2STOT SE 3
스토리지 클래스
11 - Combustible Solids

화학 및 산업

약리 정보

ATC Code · 2건

C - Cardiovascular system

QC - Cardiovascular system

Pharmacodynamics · 1건

Droxidopa is an orally active synthetic precursor of norepinephrine that increases the deficient supply of norepinephrine in patients with NOH, thereby improving orthostatic blood pressure and alleviating associated symptoms of lightheadedness, dizziness, blurred vision, and syncope through the induction of tachycardia (increased heart rate) and hypertension.

Mechanism of Action · 1건

Droxidopa crosses the blood-brain barrier where it is converted to norepinephrine via decarboxylation by L-aromatic-amino-acid decarboxylase. Norephinephrine acts at alpha-adrenergic receptors as a vasoconstrictor and at beta-adrenergic receptors as a heart stimulator and artery dilator.

Biological Half-Life2-3 hours.
Metabolism/MetabolitesDroxidopa is metabolized by aromatic L-amino acid decarboxylase.
FDA Pharmacological Classification · 6건

J7A92W69L7

DROXIDOPA

Chemical Structure [CS] - Catecholamines

Physiologic Effects [PE] - Increased Blood Pressure

The physiologic effect of droxidopa is by means of Increased Blood Pressure.

DROXIDOPA

MeSH Pharmacological ClassificationAgents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.
Absorption, Distribution and Excretion · 2건

Oral bioavailability is 90%.

Droxidopa is mainly excreted in the urine, with the main metabolite being 3-O-methyldihydroxyphenylserine.

응용 분야 · 3건

개요Droxidopa is a synthetic amino acid precursor of (-)-norepinephrine which is absorbed from the gut and metabolized to norepinephrine. In Parkinsonian patients, droxidopa added to existing levodopa/decarboxylase inhibitor therapy produces significant improvements in retropulsion, dysarthria and muscular rigidity refractory to other treatments; however, tremor was unaffected.

용도The L-threo-form Droxidopa. A synthetic amino acid precursor of Norepinephrine (N674500). Antiparkinsonian.

일반 설명L-DOPS, also called L-threo 3,4-Dihydroxyphenylserine or droxidopa is a catecholamine. L-DOPS has many clinical advantages and may be useful for treating norepinephrine deficiency. It is used for treating neurogenic orthostatic hypotension and improves norepinephrine levels. L-DOPS mediates reduction of amyloid plaques and could have a therapeutic potential for treating amyloid pathology.

추가 설명

정의ChEBI: A serine derivative that is L-serine substituted at the beta-position by a 3,4-dihydroxyphenyl group. A prodrug for noradrenalone, it is used for treatment of neurogenic orthostatic hypotension

관련 반응

6건
반응 기록 만들기
HRID 343999 반응식
HRID 343999생성물로
HRID 344000 반응식
HRID 344000생성물로
HRID 408057 반응식
HRID 408057생성물로
HRID 1599185 반응식
HRID 1599185생성물로
HRID 1599186 반응식
HRID 1599186생성물로
HRID 1762768 반응식
HRID 1762768반응물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트